BridgeBio Pharma, Inc.
BBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001743881
In the last 90 days, BridgeBio Pharma, Inc. insiders filed 0 open-market purchases and 5 sales; 475 institutions reported holding it in 13F filings for Q2 2026, worth $14.4B in total; Viking Global Investors is the only superinvestor holding it.
Holders of 5% or more of BBIO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of BridgeBio Pharma, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G/A | 6.80%13.2M shares | +1.10 ppfrom 5.70% | Feb 17, 20262 filings | May 15, 2026 | SEC |
| Farallon Capital Management, L.L.C. | 13G/A | 5.50%10.7M shares | – | Aug 3, 20261 filing | Aug 3, 2026 | SEC |
| Farallon Capital Partners, L.P. | 13G | 5.20%10.2M shares | New | May 29, 20261 filing | May 29, 2026 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13D/A | 5.00%9.79M shares | −1.10 ppfrom 6.10% | Jul 20, 202310 filings | Jul 10, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
42 Schedule 13D and 13G filings on BridgeBio Pharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 20265:30 PM ET | KKR Genetic Disorder L.P.and 8 others | 13D/A | 4.70%9.23M shares | −2.30 ppfrom 7.00%Below 5% | Aug 13, 2026 | SEC |
| Aug 3, 20268:31 AM ET | Farallon Capital Management, L.L.C.and 28 others | 13G/A | 5.50%10.7M shares | – | Jun 30, 2026 | SEC |
| Jul 27, 20264:25 PM ET | BlackRock, Inc. | 13G/A | 4.96%9.73M shares | –Below 5% | Jun 30, 2026 | SEC |
| Jul 10, 20267:03 PM ET | Viking Global Investors LPand 6 othersSuperinvestorViking Global Investors | 13D/A | 5.00%9.79M shares | −1.10 ppfrom 6.10% | Jul 9, 2026 | SEC |
| May 29, 20264:48 PM ET | Farallon Capital Partners, L.P.and 27 others | 13G | 5.20%10.2M shares | New | May 22, 2026 | SEC |
| May 15, 202612:36 PM ET | Janus Henderson Group PLC | 13G/A | 6.80%13.2M shares | +1.10 ppfrom 5.70% | Mar 31, 2026 | SEC |
| Apr 16, 20264:35 PM ET | Kumar Neil | 13G/A | 4.60%9.28M shares | −0.81 ppfrom 5.41%Below 5% | Mar 31, 2026 | SEC |
| Apr 2, 20266:40 PM ET | Viking Global Investors LPand 6 othersSuperinvestorViking Global Investors | 13D/A | 6.10%11.8M shares | −0.70 ppfrom 6.80% | Mar 31, 2026 | SEC |
| Mar 26, 20264:41 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −8.68 ppfrom 8.68%Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20268:46 PM ET | Viking Global Investors LPand 7 othersSuperinvestorViking Global Investors | 13D/A | 6.80%13.0M shares | −1.40 ppfrom 8.20% | Feb 12, 2026 | SEC |
| Feb 17, 202612:43 PM ET | Janus Henderson Group PLC | 13G | 5.70%11.0M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 20254:52 PM ET | Viking Global Investors LPand 13 othersSuperinvestorViking Global Investors | 13D/A | 8.20%15.9M shares | −1.50 ppfrom 9.70% | Nov 14, 2025 | SEC |
| Nov 14, 202512:19 PM ET | Price T Rowe Associates Inc | 13G | 1.10%885.0K shares | NewBelow 5% | Sep 30, 2025 | SEC |
| Aug 14, 20258:32 PM ET | Viking Global Investors LPand 13 othersSuperinvestorViking Global Investors | 13D/A | 9.70%18.6M shares | −0.10 ppfrom 9.80% | Aug 14, 2025 | SEC |
| Jul 29, 202511:20 AM ET | Vanguard Group Inc | 13G/A | 8.68%16.5M shares | – | Jun 30, 2025 | SEC |
| Jul 1, 20257:49 PM ET | Viking Global Investors LPand 13 othersSuperinvestorViking Global Investors | 13D/A | 9.80%18.6M shares | −1.90 ppfrom 11.70% | Jun 27, 2025 | SEC |
| May 14, 20255:52 PM ET | KKR Genetic Disorder L.P.and 8 others | 13D/A | 7.00%13.3M shares | −3.10 ppfrom 10.10% | May 12, 2025 | SEC |
| Mar 12, 20254:28 PM ET | Viking Global Investors LPand 11 othersSuperinvestorViking Global Investors | 13D/A | 11.70%22.1M shares | 0.00 ppfrom 11.70% | Jan 31, 2025 | SEC |
| Mar 7, 20256:15 PM ET | KKR Genetic Disorder L.P.and 8 others | 13D/A | 10.10%19.3M shares | – | Mar 5, 2025 | SEC |
| Feb 13, 20255:23 PM ET | Kumar Neil | 13G/A | 5.41%10.5M shares | – | Dec 31, 2024 | SEC |
| Jan 31, 20257:18 PM ET | Viking Global Investors LPand 11 othersSuperinvestorViking Global Investors | 13D/A | 11.70%22.1M shares | – | Jan 31, 2025 | SEC |
| Feb 16, 2024 | Kumar Neil | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20245:25 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 23, 2024 | State Street Corp | 13G/AOld format | – | – | – | SEC |
| Nov 22, 2023 | Viking Global Investors LPSuperinvestorViking Global Investors | 13D/AOld format | – | – | – | SEC |
| Jul 20, 2023 | Viking Global Investors LPSuperinvestorViking Global Investors | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Kumar Neil | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2023 | State Street Corp | 13GOld format | – | New | – | SEC |
| Jan 31, 20235:52 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 15, 2022 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Kumar Neil | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 3, 20224:41 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 17, 2021 | KKR Genetic Disorder L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Kumar Neil | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 12, 20217:33 PM ET | American International Group, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2021 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 5, 20217:51 AM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Jan 26, 20214:23 PM ET | Eidos Therapeutics, Inc. | 13D/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell BridgeBio Pharma, Inc. shares.
No Form 144 notices for BridgeBio Pharma, Inc. are on file.